CureVac
CureVac N.V. (CVAC) is a clinical-stage biotechnology company focused on messenger RNA (mRNA) technologies for vaccines and therapeutics. Investors should know it is development-led: value depends heavily on trial results, regulatory decisions and partnerships rather than steady revenues. The company’s market capitalisation is about $1.21 billion, reflecting both the potential of its platform and the risks typical of small-cap biotech firms. CureVac has explored infectious disease vaccines and personalised oncology approaches; progress in these programmes, licensing deals and manufacturing scale-up can materially change prospects. Past setbacks — for example with early COVID-19 candidates — show the pathway can be unpredictable. For investors this means high volatility, long timelines and binary clinical readouts. This summary is educational and not investment advice; consider sector risks, your own objectives and seek professional guidance if unsure.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping CureVac's stock as it may rise to $8.31 in the future.
Financial Health
CureVac is generating solid revenue and profits, showcasing strong cash flow and a healthy gross margin.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring CVAC
Beyond Vaccines: The mRNA Revolution
BioNTech's strong vaccine sales are fueling its expansion into new medical fields, particularly cancer treatment. This strategic shift highlights a broader investment opportunity in companies pioneering the next wave of mRNA-based therapies.
Published: August 5, 2025
Explore BasketPediatric Vaccine Rollout
This carefully selected group of stocks represents companies positioned to benefit from the full FDA approval of COVID-19 vaccines for at-risk children. Our professional analysts have identified opportunities across the entire value chain, from vaccine manufacturers to healthcare providers and clinical research organizations.
Published: July 11, 2025
Explore BasketGerman Stocks Soaring
Discover a carefully selected collection of German companies that have been dramatically outperforming their western counterparts. Our team of professional analysts has identified these standout stocks as Germany's economy shows promising signs of growth in 2025.
Published: May 15, 2025
Explore BasketWhy You’ll Want to Watch This Stock
mRNA platform potential
CureVac’s mRNA technology could enable diverse vaccines and therapeutics, a growth theme in biotech — though platform success depends on clinical proof and execution.
Clinical milestones matter
Trial readouts and regulatory steps are the main value drivers for CVAC and can cause sharp price moves; positive data can lift prospects, while failures can be costly.
Partnerships and scale
Licensing deals and manufacturing partnerships can de-risk development and accelerate commercialisation, but agreements and supply capacity are not guaranteed.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
